Drug intelligence / Profile preview

ethinyl estradiol + norethindrone acetate

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Oral
01

Overview

This specific oral combined hormonal contraceptive (OC) formulation consists of 20 mcg of ethinyl estradiol (a synthetic estrogen) and 1 mg of norethindrone acetate (a progestin). In the context of polycystic ovary syndrome (PCOS), particularly in women of later reproductive age (40-49 years), it is used as a first-line medical therapy to manage clinical and biochemical hyperandrogenism, regulate menstrual cycles, and prevent endometrial hyperplasia by inducing regular withdrawal bleeding. The University of Virginia studied this formulation in a randomized, double-blind, crossover trial (NCT03905941) to determine its relative desirability and efficacy compared to metformin, using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) score as a proxy for patient satisfaction. The mechanism involves the suppression of pituitary gonadotropin secretion, which inhibits ovulation and reduces ovarian androgen production.

Brand names
Loestrin 1/20Junel 1/20Microgestin 1/20Larin 1/20Gildess 1/20Aurovela 1/20Hailey 1/20
Other names
oral combined hormonal contraceptivesOCsbirth control pillethinyl estradiol 20 mcg / norethindrone acetate 1 mg
02

Targets

SHBG (Sex hormone-binding globulin)PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on ethinyl estradiol + norethindrone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinyl estradiol + norethindrone acetate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call